Twinstrand Therapeutics is a privately-owned biopharmaceutical company focused on discovering and developing targeted prodrugs. The Company’s lead compound for the treatment of cancer has entered Phase I trials. Twinstrand’s proprietary technology has potential for the treatment of a broad range of viral, fungal and parasitic disease.

Search

Downloads

Prodrug mechanism
September 22, 2006

Patent "Ricin-like toxins for the treatment of cancer"
June 13, 2006

Patent "Antiviral Ricin-Like Proteins"
December 25, 2001

Patent "Ricin-like toxin variants for treatment of cancer, viral or parasitic infections"
April 30, 1998

Patent "Antiviral Ricin-like proteins"
April 29, 1997